Compare UiPath Inc (PATH) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Zoetis Inc — how do they compare? UiPath Inc trades at $10.65 (market cap $6.24B), while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: Zoetis Inc is far larger — about 5.1× UiPath Inc's market cap, and Zoetis Inc pays a 2.81% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| PATH | ZTS | |
|---|---|---|
Market Cap | $6.24B | $31.59B |
Sector | Technology | Health |
52-Week High | $19.29 | $156.76 |
52-Week Low | $9.38 | $71.91 |
Enterprise Value | $5.01B | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $12.04, down 0.91% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while narrowing net losses signal a path toward sustained profitability. Recent news highlights strong annual recurring revenue growth to $1.9B and strategic AI automation developments through its Maestro platform.
The investment outlook is cautiously optimistic, supported by analyst consensus and improving margins, but risks include competitive pressures in AI automation and volatility in software spending. The stock presents a potential opportunity if execution on profitability continues, though near-term earnings misses warrant monitoring.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
